Lipocine Inc. (LPCN) research
Lipocine Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.12
- As of
Lipocine Inc. (LPCN): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-16.
As of . Source: SEC EDGAR filings for LPCN. Method and limitations.
Share the LPCN intelligence card
See LPCN live in the terminal
Track LPCN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live LPCN terminal, freeActive signals for LPCN
- highCONSENSUS_BUY
3 tracked funds increased LPCN this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased LPCN this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +80% to LPCN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +470% to LPCN (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +152% to LPCN (2026Q2)
FREE, NO ACCOUNT
Every signal on LPCN, as it fires
You are seeing 5 of 20 signals recorded on LPCN since 2026-05-24.
The five above landed across 2 days. The other 15 were recorded on 4 other days. 12 of the 20 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LPCN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 53630X203 · 2026Q2 | $217K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 53630X203 · 2026Q2 | $208K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 53630X203 · 2026Q2 | $177K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LPCN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
LPCN against its peers
LPCN's operating margin of -524.7% ranks in the 64th percentile of 6 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | LPCN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.0M USD | 445000 USD | 72 | 8 |
| Operating margin | -524.7% | -2670.1% | 64 | 6 |
| Net margin | -487.1% | -2327.7% | 64 | 6 |
| Return on equity | -66.5% | -113.8% | 82 | 18 |
Peers (22): SNSE, CMMB, VYNE, NCEL, MRKR, DYAI, ALLR, KTTA, TVRD, ACTU, INTI, NEUP, GRDX, ESLA, PTN, BCDA, AEON, BIVI, ATOS, PASG, CLRB, LTRN. Left out: PBM (period gap), FNCHQ (period gap), CTXR (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (LPCN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more LPCN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to LPCNand get the insider, 13F, options, and confluence read in one view.